IOncology

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting recently concluded in Barcelona, Spain, bringing together the world's leading oncology experts. At this year's conference, Dr. Yuhong Zhou from Zhongshan Hospital, Fudan University, presented a phase II multicenter clinical trial that explored the efficacy and safety of surufatinib combined with gemcitabine in soft tissue sarcoma (STS) patients who had failed anthracycline chemotherapy or anlotinib monotherapy. The study offers new perspectives for clinical practice.

From September 13 to 17, 2024, the European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. At this prestigious conference, the DUBHE-H-308 study led by Dr. Shukui Qin from Nanjing Tianyinshan Hospital, affiliated with China Pharmaceutical University, was selected for an LBA oral presentation (Abstract No.: LBA38). On September 13, from 16:00 to 16:10 local time, Dr. Shukui Qin presented the study online. Oncology Frontier attended the event and compiled the key findings of this significant research for readers.

The ESMO Annual Meeting 2024, held from September 13 to 17 in Barcelona, Spain, showcased the latest breakthroughs in oncology. Among them was a new study from the team led by Academician Jia Fan, Dr. Jian Zhou, and Dr. Xinrong Yang from Zhongshan Hospital, Fudan University, in collaboration with Burning Rock Biotech. The research, which was presented as a poster at the conference, provided preliminary evidence that the methylation and mutation of circulating tumor DNA (ctDNA) play a crucial role in assessing minimal residual disease (MRD) status and predicting recurrence after curative liver cancer surgery. This study offers new strategies and tools for postoperative management of early-stage liver cancer patients. With further refinement and large-scale clinical validation, this method could become an important adjunct in postoperative monitoring, potentially improving patient survival outcomes.

Evidence from the Breast Cancer Customization Project suggests that a more comprehensive approach is needed to help patients find the motivation to adopt an active lifestyle. Physical activity is often recommended by clinicians as a lifestyle intervention to help prevent and manage non-communicable diseases, including cancer. It is also essential for the quality of life of patients diagnosed with cancer.

Gastrointestinal stromal tumors (GIST) are mesenchymal tumors driven by mutations in oncogenes. In recent years, various types of small-molecule tyrosine kinase inhibitors (TKIs) have provided new treatment options for patients with advanced GIST, but there remains a significant unmet need in clinical care. During the 2024 ESMO Annual Meeting, Dr. Jian Li's team from Peking University Cancer Hospital presented updated data from the follow-up treatment analysis of the INTRIGUE China bridging study on ripretinib, offering further insights into the clinical application of such novel drugs.

With the rapid development of genetic testing technology, the treatment strategies for patients with cancer of unknown primary (CUP) are undergoing revolutionary changes. During the 2024 ESMO Congress, the World CUP Alliance held a special "Roundtable on Access & Awareness of Precision Oncology" at the ESMO Congress, looking forward to the current treatment of CUP patients. After the meeting, Oncology Frontier specially invited Prof. Xichun Hu from Fudan University Shanghai Cancer Center, Prof. Linda Mileshkin from Peter MacCallum Cancer Center in Australia, Prof. Manel Esteller from Josep Carreras Leukemia Research Institute in Spain, and Prof. Qinghua Xu from Hangzhou Gene Help Technology Co., Ltd Help to gather together and discuss in depth the new advances in the treatment of CUP. From the positive data of the CUPISCO trial to the results of the Fudan CUP-001 study, the experts not only shared cutting-edge research results but also proposed valuable insights on how to improve the diagnostic accuracy for CUP patients and promote the implementation of personalized treatment plans, bringing new treatment hopes for CUP patients worldwide.

New data shows that breastfeeding does not increase the risk of breast cancer recurrence or developing secondary breast cancer, nor does it pose any health risks to the child.

With the rapid advancement of science and technology, there is growing hope that more cancers can be intercepted at their earliest stages. The European Society for Medical Oncology (ESMO) is deeply exploring the field of prevention to ensure that oncologists are educated and guided in this evolving area.

From September 13 to 17, the 2024 ESMO Annual Meeting is in full swing in Barcelona, Spain. Oncology Frontier is attending the event and bringing you first-hand insights from the conference. During the non-metastatic non-small cell lung cancer (NSCLC) paper session held on September 13, Dr. Suresh Senan from Amsterdam, Netherlands, presented the latest results from the ADRIATIC study, where subgroup analysis further supports previous practice-changing findings.

The European Society for Medical Oncology Congress 2024(ESMO 2024) opened on September 13, in Barcelona,Spain. Lung cancer remains one of the key areas of focus,with several groundbreaking studies presented at the conference. Oncology Frontier invited Dr.Yuankai Shi, principal investigator of the INSPIRE study from the Cancer Hospital Chinese Academy of Medical Sciences,to share the latest data from this year's ESMO conference and discuss the clinical value of the study in treating anaplastic lymphoma kinase(ALK)-positive advanced non-small cell lung cancer(NSCLC).